In 2020, the Clinical Research Office helped the Cancer Center realize various accomplishments in alignment with its mission – to deliver new and promising cancer treatments in order to improve the lives of the patients at the UF Health Cancer Center.
- The CRO supported 4,941 accruals in cancer clinical trials.
- Enrollments to treatment remained strong at 409 despite temporary suspensions of research due to COVID-19.
- By the end of 2020, 78% of all eligible CRO staff were research certified through either the Society of Clinical Research Associates or the Association of Clinical Research Professions.
- The CRO is now actively recruiting patients for Precision Promise, an initiative of the Pancreatic Cancer Action Network and the first large-scale precision medicine trial designed to transform outcomes for patients with pancreatic cancer. UF Health is one of 15 national centers chosen to participate.
- The UFHCC is a member of the National Cancer Institute’s Experimental Therapeutics Clinical Trial Network, bringing new novel therapies directly to UFHCC patients from other top cancer centers around the country.
The UF Health Cancer Center has 13 Disease Site Groups, 10 disease-specific, one pediatric and two disease-agnostic, that consist of both research and clinical leaders. Each Disease Site Group is charged with developing and maintaining a portfolio of trials that brings forward scientific hypotheses developed in the Cancer Center Research Programs and is relevant to the Cancer Center’s catchment area. All newly proposed interventional trials must be endorsed first by the appropriate Disease Site Group. During the first stage of review, Disease Site Groups emphasize prioritization, catchment area and clinical needs. In 2020, the Disease Site Groups reviewed 139 interventional trials, only 47 of which were endorsed. This demonstrates that the Disease Site Groups are highly selective in bringing only the best suited clinical trial options forward for their patients.